Skip to main content
. 2022 Dec 23;8(51):eadc8911. doi: 10.1126/sciadv.adc8911

Fig. 3. ACTR5 controls the CDKN2A and CDK6 cell cycle signaling in HCC.

Fig. 3.

(A and C) Western blot of ACTR5, CDKN2A, CDK6, Rb, p-Rb, E2F1, and β-actin in (A) dCas9-Krab–expressing HCC (HepG2 and SNU475) and glioblastoma (U251 and U87) cells, and (C) vector versus ACTR5-TST–expressing HepG2-dCas9-Krab cells transduced with sgiNTC and sgiACTR5. (B) Cell cycle monitored by 5-Ethynyl-2′-deoxyuridine incorporation in HepG2-dCas9-Krab cells transduced with sgiNTC and sgiACTR5 (n = 3). (D) Growth competition assay of vector versus ACTR5-TST–expressing HepG2-dCas9-Krab cells transduced with RFP-labeled sgiNTC and sgiACTR5 (n = 3 each group). (E) Effect of targeting ACTR5 on CDKN2A- and CDK6-triggered cell cycle signaling. Data are presented as means ± SEM. *P < 0.01 by two-sided Student’s t test.